Authors:

Cheng Lee Yi

Department of Gastroenterology and Hepatology, Catholic Universityof Daegu School of Medicine, Korea

Abstract:

NAs, which reduce viral load, HBeAg seroconversion, and in certain cases, HBsAg seroconversion, have improved patient prognosis. The duration and end point of NA therapy, on the other hand, are still up for debate. HBeAg seroconversion and undetectable HBV DNA status are maintained for at least 6-12 months for HBeAg-positive patients, and undetectable HBV DNA status on three separate occasions 6 months apart for HBeAg-negative patients if they have been treated for at least 2 years, according to current international guidelines. The long-term viability of NA, particularly after stopping therapy, is unknown. If a persistent serological and/or virological response fails and a high off-treatment virological relapse develops, a proportion of patients who cease NA medication after HBeAg seroconversion may require retreatment.

Keywords:
seroconversion, durability, relapse

Citation:

Cheng Lee Yi. Is It Necessary to Continue Oral Antiviral Treatment for Chronic Hepatitis B Virus Infection?. Japanese Journal of Gastroenterology 2023.